DUBLIN, June 7- Royalty Pharma raised its hostile bid for Irish drug firm Elan to a potential $8 billion on Friday, after just 7.5 percent of the target company's shareholders accepted its previous offer.
The two-day FDA advisory committee meeting is not expected to bring about a major boost in sales for the onetime multibillion dollar product. Glaxo has said it has no plans to promote Avandia again, even if the FDA panel recommends lifting restrictions on sales of the drug, whose generic name is rosiglitazone.
The two-day FDA advisory committee meeting is not expected to bring about a major boost in sales for the onetime blockbuster product.
Avandia's U.S. patent lapsed in 2011, a year after the FDA heavily restricted its use due to ambiguity about possible increased risk of heart attack and stroke seen in a large trial called RECORD, as well as a review of dozens of other studies.
The Federal Reserve won't change course on quantitative easing this week, Steve Weiss of Short Hills Capital says.
Tuesday, 18 Jun 2013 | 7:10 AM ETAn airline passenger records a Chinese cargo handler as he tosses boxes of something on to and off of a conveyor belt for shipment. Hopefully, the cargo was packed well.
Tuesday, 18 Jun 2013 | 9:33 AM ETPlans to take PC maker Dell private by leveraging the company's balance sheet are misguided, CNBC's Jim Cramer said on "Squawk on the Street" Tuesday, because the company is facing lower margins and an increased competition from rival Hewlett Packard.